Successful implantation of HeartWare HVAD left ventricular assist device with concomitant ascending and sinus of valsalva aneurysms repair

Takeda, Koji; Ahmad, Umraan; Malaisrie, S. Chris; Lee, Richard; McCarthy, Patrick M.

doi:10.1007/s10047-012-0628-6

Cited by 9 publications

(8 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, a successful implantation of HeartWare LVAD with concomitant ascending and sinus vasalva anuerysms repair has been described in previous research [8]. These experiences show that low mortality and morbidity after LVAD implantation can be achieved even in patients requiring combined surgical procedures.…”

Section: Discussionmentioning

confidence: 82%

Left ventricular assist device implantation with concomitant left ventricular reconstruction without patchplasty

et al. 2014

View full text Add to dashboard Cite

In this case report, we describe a 66-year-old patient with a massive LV aneurism which resulted after myocardial infarction. Due to severe LV function impairment, it was decided to perform left ventricular reconstruction surgery and, at the same time, left ventricular assist device implantation as a bridge to transplantation. The entire procedure was completed without using any patch material. The patient had an uneventful recovery and was discharged home after 18 days. After 1-year follow-up no adverse events were observed.

show abstract

Section: Discussionmentioning

confidence: 82%

Left ventricular assist device implantation with concomitant left ventricular reconstruction without patchplasty

et al. 2014

View full text Add to dashboard Cite

show abstract

“…It was demonstrated that the morphological RV (functional LV) can be cannulated using either diaphragmatic surface or the free wall without significant changes in standard implantation technique with good outcome [42]. Furthermore, HVAD can be successfully used in patients with heart failure requiring complex aortic pathologies [43].…”

Section: Hvad In the Presence Of Atypical Anatomy And With Concomitant mentioning

confidence: 98%

HeartWare miniaturized intrapericardial ventricular assist device: advantages and adverse events in comparison to contemporary devices

Sabashnikov

Mohite

Simon

et al. 2013

Expert Review of Medical Devices

View full text Add to dashboard Cite

Increasing incidence of end-stage heart failure and limited availability of donor organs have led to longer waiting times for cardiac transplantation and subsequently increasing mortality. Ventricular assist device therapy is fast becoming an accepted alternative treatment to treat end-stage heart failure and is being implemented as a bridge to decision, bridge to myocardial recovery, bridge to heart transplantation or as a destination therapy. LVADs not only enable hemodynamic stabilization and recovery of secondary organ failure in severely ill patients, but have also been shown to reduce pulmonary vascular resistance in nontransplantable candidates. Technology of ventricular assist devices has evolved over several decades of time and generations of devices. The HVAD® Pump (HeartWare International, Inc., MA, USA) is a third-generation, miniaturized, continuous-flow ventricular assist device. Due to its miniaturized housing and intrapericardial placing, it can be used proficiently to support the right ventricle and has also demonstrated great utility in minimally invasive and off-pump implantation, exchange and explantation. It is favored for similar reasons in adolescents and in heart failure due to complex congenital heart disease. The purpose of this article is to review the clinical use of HeartWare® Ventricular Assist System (HeartWare System; HeartWare International, Inc.) with different strategies pertaining to its advantages and adverse events in comparison with contemporary devices.

show abstract

“…Medical management can be a starting option, targeting fluid overload with diuretics, reducing afterload with vasodilators ( 12 ) along with utilizing angiotensin-converting enzyme inhibitors, calcium channel blockers, or beta blockers ( 86 ).…”

Section: How To Manage Ar or Prevent De Novo Ar In...mentioning

confidence: 99%

Reciprocal interferences of the left ventricular assist device and the aortic valve competence

Vriz

Ali

Shaik

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Patients suffering from end-stage heart failure tend to have high mortality rates. With growing numbers of patients progressing into severe heart failure, the shortage of available donors is a growing concern, with less than 10% of patients undergoing cardiac transplantation (CTx). Fortunately, the use of left ventricular assist devices (LVADs), a variant of mechanical circulatory support has been on the rise in recent years. The expansion of LVADs has led them to be incorporated into a variety of clinical settings, based on the goals of therapy for patients ailing from heart failure. However, with an increase in the use of LVADs, there are a host of complications that arise with it. One such complication is the development and progression of aortic regurgitation (AR) which is noted to adversely influence patient outcomes and compromise pump benefits leading to increased morbidity and mortality. The underlying mechanisms are likely multifactorial and involve the aortic root-aortic valve (AV) complex, as well as the LVAD device, patient, and other factors, all of them alter the physiological mechanics of the heart resulting in AV dysfunction. Thus, it is imperative to screen patients before LVAD implantation for AR, as moderate or greater AR requires a concurrent intervention at the time of LVADs implantation. No current strict guidelines were identified in the literature search on how to actively manage and limit the development and/or progression of AR, due to the limited information. However, some recommendations include medical management by targeting fluid overload and arterial blood pressure, along with adjusting the settings of the LVADs device itself. Surgical interventions are to be considered depending on patient factors, goals of care, and the underlying pathology. These interventions include the closure of the AV, replacement of the valve, and percutaneous approach via percutaneous occluding device or transcatheter aortic valve implantation. In the present review, we describe the interaction between AV and LVAD placement, in terms of patient management and prognosis. Also it is provided a comprehensive echocardiographic strategy for the precise assessment of AV regurgitation severity.

show abstract

Successful implantation of HeartWare HVAD left ventricular assist device with concomitant ascending and sinus of valsalva aneurysms repair

Cited by 9 publications

References 5 publications

Left ventricular assist device implantation with concomitant left ventricular reconstruction without patchplasty

Left ventricular assist device implantation with concomitant left ventricular reconstruction without patchplasty

HeartWare miniaturized intrapericardial ventricular assist device: advantages and adverse events in comparison to contemporary devices

Reciprocal interferences of the left ventricular assist device and the aortic valve competence

Contact Info

Product

Resources

About